Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Net Income (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Net Income for 6 consecutive years, with -$125.0 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 36.31% to -$125.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$256.3 million through Dec 2025, up 23.41% year-over-year, with the annual reading at -$256.3 million for FY2025, 23.41% up from the prior year.
  • Net Income hit -$125.0 million in Q4 2025 for Lyell Immunopharma, down from -$34.0 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$11.3 million in Q4 2022 to a low of -$196.2 million in Q4 2024.
  • Historically, Net Income has averaged -$60.4 million across 5 years, with a median of -$52.4 million in 2023.
  • Biggest five-year swings in Net Income: skyrocketed 76.0% in 2022 and later tumbled 362.66% in 2023.
  • Year by year, Net Income stood at -$47.2 million in 2021, then surged by 76.0% to -$11.3 million in 2022, then plummeted by 362.66% to -$52.4 million in 2023, then tumbled by 274.31% to -$196.2 million in 2024, then surged by 36.31% to -$125.0 million in 2025.
  • Business Quant data shows Net Income for LYEL at -$125.0 million in Q4 2025, -$34.0 million in Q3 2025, and -$43.9 million in Q2 2025.